Survival of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Nationwide Epidemiological Analysis in Turkiye

被引：0
|
作者：
Kurtuncu, Murat [1 ]
Ozturk, Bilgin [2 ]
Taskiran, Esra [3 ]
Demir, Serkan [4 ]
Ata, Naim [5 ]
Ulgu, Mustafa Mahir [5 ]
Birinci, Suayip [5 ]
Tuncer, Asli [6 ]
机构：
[1] Istanbul Univ, Dept Neurol, Istanbul Fac Med, Istanbul, Turkiye
[2] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Neurol, Ankara, Turkiye
[3] Antalya Training & Res Hosp, Neurol Clin, Antalya, Turkiye
[4] Sancaktepe Sehit Prof Dr Ilhan Varank Training &, Dept Neurol, Istanbul, Turkiye
[5] Minist Hlth, Ankara, Turkiye
[6] Hacettepe Univ, Dept Neurol, Sch Med, Ankara, Turkiye
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1186/358
引用
收藏
页码：780 / 781
页数：2
相关论文
共 50 条
  • [21] Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Kim, Woojun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2020, 16 (03): : 355 - 368
  • [22] Efficacy and Safety of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP3 - NP4
  • [23] Quantitative Susceptibility Mapping in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Kim, W.
    Lee, J. E.
    Lee, K. S.
    Nam, Y.
    Jang, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 438 - 438
  • [24] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Tatchaporn Ongphichetmetha
    Jiraporn Jitprapaikulsan
    Sasitorn Siritho
    Natthapon Rattanathamsakul
    Thammachet Detweeratham
    Naraporn Prayoonwiwat
    Scientific Reports, 14
  • [25] Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach
    Ota, Miho
    Sato, Noriko
    Okamoto, Tomoko
    Noda, Takamasa
    Araki, Manabu
    Yamamura, Takashi
    Kunugi, Hiroshi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (06) : 515 - 520
  • [26] Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder
    Uzawa, A.
    Mori, M.
    Masuda, H.
    Ohtani, R.
    Uchida, T.
    Aoki, R.
    Kuwabara, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 202 (02): : 239 - 248
  • [27] Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis
    Hyun, J. -W.
    Jang, H.
    Yu, J.
    Park, N. Y.
    Kim, S. -H.
    Huh, S. -Y.
    Kim, W.
    Park, M. S.
    Oh, J.
    Park, K. D.
    Kim, H. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 401 - 402
  • [28] Prevalences and incidences of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea
    Kim, Jee-Eun
    Park, Sang-hyun
    Han, Kyungdo
    Kim, Ho-Jin
    Shin, Dong-wook
    Kim, Sung-Min
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP44 - NP44
  • [29] Sleep in multiple sclerosis and neuromyelitis optica spectrum disorder—the SEMN study
    Nise Alessandra Carvalho Sousa
    Carlos Mauricio Oliveira de Almeida
    Satiko Andrezza Ferreira Takano
    Siane Prado Lima Souza
    Ronaldo Marques Pontes Rabelo
    Sleep and Breathing, 2023, 27 : 2453 - 2458
  • [30] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    Siritho, Sasitorn
    Rattanathamsakul, Natthapon
    Detweeratham, Thammachet
    Prayoonwiwat, Naraporn
    SCIENTIFIC REPORTS, 2024, 14 (01)
12345